This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.J Ahmad , MA Siddiqui , H Ahmad . Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576–1581.
2.T Arnesen , M Trommald . Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy. 2004;9:43–50.
3.AH Barnett , SC Bain , P Bouter , et al; for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–1961.
4.AG Bertoni , JS Krop , GF Anderson , Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–475.
5.H Bleichrodt , M Johannesson . Standard gamble, time trade-off and rating scale: Experimental results on the ranking properties of QALYs. J Health Econ. 1997;16:155–175.
6.S Braun , A Prenzler , T Mittendorf , Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance [in German]. Gesundheitswesen. 2009;71:19–23.
7.AH Briggs , AE Ades , MJ Price . Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework. Med Decis Making. 2003;23:341–350.
8.GC Brown , MM Brown , S Sharma , Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:18–24.
10.JP Casas , W Chua , S Loukogeorgakis , Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005;366:2026–2033.
12.WD Comper , TM Osicka , G Jerums . High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis. 2003;41:336–342.
13.DJ Cook , GH Guyatt . Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy. Ann Intern Med. 1999;131:707–708.
14.P Dolan , C Gudex , P Kind , Valuing health states: A comparison of methods. J Health Econ. 1996;15:209–231.
16.A Gandjour , F Kleinschmit , KW Lauterbach ; INTERCARE International Investigators. European comparison of costs and quality in the prevention of secondary complications in Type 2 diabetes mellitus (2000–2001). Diabet Med. 2002;19:594–601.
19.L Golan , JD Birkmeyer , HG Welch . The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660–667.
21.Guideline of the American Diabetes Association (ADA). Nephropathy in Diabetes. Diabetes Care. 2004;27 (Suppl):79S–83S.
23.Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259.
26. BL Kasiske , RS Kalil , JZ Ma , Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med. 1993;118:129–138.
28. I Koester , L von Ferber , P Ihle , The cost burden of diabetes mellitus: The evidence from Germany—the CoDiM Study. Diabetologia. 2006;49:1498–1504.
29.RJ Koopman , AG III Mainous , VA Diaz , Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3:60–63.
31.EJ Lewis , LG Hunsicker , RP Bain , The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462.
32.EJ Lewis , LG Hunsicker , WR Clarke , Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
33.DB Matchar , DC McCrory , LA Orlando , Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16–29.
37.LK Niskanen , I Penttila , M Parviainen , Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996;19:486–493.
38. HH Parving , H Lehnert , J Brochner-Mortensen , The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
39.AB Rosen , BH Hamel , MC Weinstein , Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89–99.
50.The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787–1792.